- $3.41bn
- $3.07bn
- $366.38m
- 85
- 12
- 92
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 117.56 | ||
| PEG Ratio (f) | 2.74 | ||
| EPS Growth (f) | 75.32% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.36 | ||
| Price to Tang. Book | 7.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.87% | ||
| Return on Equity | -1.01% | ||
| Operating Margin | -7.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13.82 | 111.53 | 180.29 | 273.7 | 366.38 | 448.04 | 539.39 | 249.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +68.52 | +84.55 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Directors
- Michael Carrel NEC (50)
- Danny Dearen PRE
- Raymond Cohen CEO (62)
- Rinda Sama COO (42)
- John Woock CMO (38)
- Alfred Ford OTH (50)
- Karen Noblett OTH (58)
- Esteban Lopez DRC (49)
- David Demski IND (63)
- Jane Kiernan IND (60)
- Robert McNamara IND (64)
- Nancy Snyderman IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 2nd, 2012
- Public Since
- October 31st, 2018
- No. of Shareholders
- 715
- No. of Employees
- 797
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 51,003,429
- Address
- 26 Technology Drive, IRVINE, 92618
- Web
- https://www.axonics.com/
- Phone
- +1 9493966322
- Auditors
- BDO USA, LLP
Upcoming Events for AXNX
Axonics Inc Annual Shareholders Meeting
Q2 2024 Axonics Inc Earnings Release
Similar to AXNX
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Axonics share price?
As of Today at 19:03 UTC, shares in Axonics are trading at $66.95. This share price information is delayed by 15 minutes.
How has the Axonics share price performed this year?
Shares in Axonics last closed at $66.95 and the price had moved by +12.46% over the past 365 days. In terms of relative price strength the Axonics share price has underperformed the S&P500 Index by -6.41% over the past year.
What are the analyst and broker recommendations for Axonics?
The overall consensus recommendation for Axonics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Axonics dividend yield?
Axonics does not currently pay a dividend.
Does Axonics pay a dividend?
Axonics does not currently pay a dividend.
When does Axonics next pay dividends?
Axonics does not currently pay a dividend.
How do I buy Axonics shares?
To buy shares in Axonics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Axonics?
As of the previous close price of $66.95, shares in Axonics had a market capitalisation of $3.41bn.
Where are Axonics shares listed?
Here are the trading details for Axonics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AXNX
What kind of share is Axonics?
Based on an overall assessment of its quality, value and momentum Axonics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Axonics share price forecast for 2024?
The analyst consensus target price for shares in Axonics is $71.73. That is 7.14% above the last closing price of $66.95.
Analysts covering Axonics currently have a consensus Earnings Per Share (EPS) forecast of $0.45 for the next financial year.
What is the trend in the Axonics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Axonics. Over the past six months, its share price has outperformed the S&P500 Index by +8%.
As of the last closing price of $66.95, shares in Axonics were trading +10.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Axonics PE Ratio?
The Axonics PE ratio based on its reported earnings over the past 12 months is 117.56. The shares last closed at $66.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Axonics?
Axonics' management team is headed by:
- Michael Carrel - NEC
- Danny Dearen - PRE
- Raymond Cohen - CEO
- Rinda Sama - COO
- John Woock - CMO
- Alfred Ford - OTH
- Karen Noblett - OTH
- Esteban Lopez - DRC
- David Demski - IND
- Jane Kiernan - IND
- Robert McNamara - IND
- Nancy Snyderman - IND